

# Hemostasis in the Premature Neonate

Gail M Annich, MD MS FELSO

***Department of Critical Care Medicine***

PICU Associate Staff

Director of Quality & Safety

Director of CCRT/Code Blue

***The Hospital for Sick Children***


Director of Resuscitation and Code Response Teams

Mass Casualty Medical Lead

***University of Toronto***

Professor of Paediatrics and Communicable Diseases

# The Challenges of ECLS:






Management of Anticoagulation and Hemostasis for Pediatric Extracorporeal Membrane Oxygenation

Arun Saini MD, Philip C. Spinella MD R BC




# Blood Surface Interaction






# Fibrinolytic Pathway




# Hemorrhagic Complications of ECLS



# *In Utero* Development of Coagulation Factors

## Fetal Development of Hemostatic Factors



Adapted from Toulon et al Thrombosis and Haemostasis 116: 9-16 2016



UNIVERSITY OF TORONTO  
FACULTY OF MEDICINE

Healthier Children. A Better World.

**SickKids**

THE HOSPITAL FOR  
SICK CHILDREN




# Primary Hemostasis of the Preterm Neonate


- Platelets exist by 5 weeks gestation
- Platelet count is usually normal (adult) levels by 22 weeks gestation
- Platelets are hyporeactive the more premature due too lack of alpha adrenergic receptors.
- Also have low, high molecular weight kininogen (HMWK)
- Compensatory to this they have higher levels of vWF and thus they seem to have a relatively normal primary response to hemorrhage.




# vWF and HMWK of the Preterm Neonate




# Coagulation Factor Levels from Neonate to Adult



# Coagulation Factor Levels in Preterm Infants Over 6 Mos




# Physiologic Regulation of Coagulation & Fibrinolysis



# Plasminogen Levels in Preterm Infants Over 6 Mos


Preterm Infants 30-36 weeks over 6 mos of Life



# Hemostasis of the Preterm Neonate



R. Rajagopal et al. / *Seminars in Fetal & Neonatal Medicine* 21 (2016) 50–56

51



**Fig. 1.** Components of the hemostatic system in preterm infants compared with adults. The overall outcome appears to be balanced as spontaneous thrombosis or bleeding are rare in the absence of blood flow or vessel wall disturbances. vWF, von Willebrand factor; HMWK, high-molecular-weight kininogen.

# Anticoagulant Choice



Warkentin. *Best Pract Res Clin Haematol* 2004; 17: 105-125





# Unfractionated Heparin (UNFH)

- Default anticoagulant for ECLS
- Derived from bovine and porcine intestine and lung
- ~ 1/3 of UNFH molecules contain the pentasaccharide sequence that allows for binding to AT
- AT – Thrombin - UNFH complex produces 1000 X increase in AT activity
- Hepatic metabolism, renal excretion
- Rapidly neutralized by protamine (salmon)

# Direct Thrombin Inhibitor General Guide to Dosing

DRUG	DOSE		MONITORING**		BLEEDING**	
	CHILD	ADULT	CHILD	ADULT	CHILD	ADULT
Argatroban  Hepatic clearance	0.1-10 ug/kg/min In HIT*; 0.75 ug/kg/min Adjust dose by 0.1–0.25 ug/kg/min In hepatic compromise 0.2 ug/kg/min	0.2ug/kg/min* in HIT; 2.0 ug/kg/min and adjust re PTT	PTT 1.5- 3X (<100 sec) 2 hr post initiation ACT 160-200	PTT 40-120 2 hr post initiation ACT 170-200 Esper et al 2014 Phillips & Khoury 2014	FVIIa 30-90 ug/kg	FVIIa 30-90 ug/kg
Bivalirudin  Proteolysis 75% renal 25% Clearance	Bolus 0.125-0.25 mg/kg Infusion 0.125-0.2 mg/kg/h (if initial drug)  Infusion 0.1-0.8, if tx from UFH	Infusion 0.08-0.2 mg/kg/h Dose increase up to 0.03 mg/kg/h	PTT 50-70 2 hr post initiation ACT 160-200	PTT 40-120 2 hr post initiation ACT 200-220	FVIIa 30-90 ug/kg  **<10 case reports	FVIIa 30-90 ug/kg

# Coagulation and Anticoagulation Testing Variability

Parameter	15 days - 4 weeks	4-5 months	6-11 months	1-5 years	6-10 years	11-17 years	Adults
PT (sec)	112.19±1.61	111.97±1.29	111.98±1.30	113.19±1.41	117.10±1.45	118.10±1.41	119.02±1.22
(20°)	0.991(0.8-1.13)	0.971(0.8-1.17)	0.981(0.8-1.13)	0.991(0.8-1.21)	1.041(0.9-1.30)	1.041(0.9-1.24)	1.051(0.8-1.07)
(30°)	1.001(0.8-1.09)	1.001(0.8-1.08)	1.001(0.8-1.083)	1.001(0.8-1.038)	0.951(0.6-1.112)	0.911(0.7-1.091)	1.051(0.8-1.038)
(p=30)	(p=30)	(p=220)	(p=176)	(p=537)	(p=123)	(p=202)	(p=64)
PTT (sec)	35.51(7.5-55.6)	33.31(6.4-40.7)	32.41(5-40.7)	31.51(4-39.1)	31.51(3.5-38.1)	31.51(2.5-38.4)	31.71(1.5-38.3)
(20°)	1.151(0.9-1.43)	1.11(0.8-1.30)	1.071(0.8-1.31)	1.051(0.8-1.31)	1.041(0.8-1.28)	1.021(0.8-1.28)	1.041(0.8-1.20)
(p=30)	(p=30)	(p=310)	(p=174)	(p=490)	(p=124)	(p=208)	(p=64)
PTT (sec)	39.01(32.2-45.6)	33.31(30-43.3)	34.31(31-45.3)	32.41(3-38.4)	33.01(3.5-42.4)	32.01(3-41.4)	32.81(3-39.5)
(20°)	1.281(1.2-1.43)	1.11(0.8-1.38)	1.121(0.8-1.49)	1.071(0.8-1.26)	1.081(0.8-1.39)	1.051(0.6-1.55)	1.081(0.8-1.31)
(p=30)	(p=30)	(p=22)	(p=31)	(p=34)	(p=34)	(p=31)	(p=44)
PTT (sec)	2.51(1.8-4.02)	2.261(2.1-3.6)	2.231(1.5-3.60)	2.231(0.8-3.1)	2.201(0.8-3.5)	2.201(0.7-3.0)	2.251(1.7-3.42)
(p=34)	(p=289)	(p=163)	(p=453)	(p=113)	(p=209)	(p=44)	
PTT (sec)	2.401(1.5-3.10)	2.101(1.4-3.7)	2.201(0.8-3.67)	2.201(0.8-3.97)	2.151(1.7-3.57)	2.201(0.8-3.19)	2.261(1.3-3.22)
(p=30)	(p=30)	(p=53)	(p=115)	(p=115)	(p=36)	(p=63)	(p=44)

Toulon et al Thombosis and Haemostasis 116: 9-16 2016

# Challenges with Present Monitoring Tests

ACT	Least related to heparin dose on ECMO Least responsive to heparin dose changes More frequent sampling Results influenced by reagent used Influenced by thrombocytopenia, hematocrit, and hypothermia
APTT	Over 300 reagents available Reagent changes heparin sensitivity No difference in bleeding or thrombosis risk compared to Anti-Xa Influenced by plasma free hemoglobin and hyperbilirubinemia
Anti-Xa	Assay results influenced by assay type <ul style="list-style-type: none"><li>- Exogenous antithrombin</li><li>- Dextran sulfate additive</li><li>- Neither</li></ul> Influenced by plasma free hemoglobin, hyperbilirubinemia, and hypertriglyceridemia
TEG/ROTEM	High interoperator variation Results influenced by assay used and plasma free hemoglobin

## Hematologic concerns in extracorporeal membrane oxygenation

Jonathan Sniderman M D, CM<sup>1</sup> | Paul Monagle M BBS, M D, FRACP, FCCPA, FCCP<sup>2</sup> |  
Gail M. Annich M D, M S, FRCP(C)<sup>3</sup> | Graeme MacLaren M BBS, M Sc, FCCM, FELSO<sup>1,4,5</sup>

*Res Pract Thromb Haemost.* 2020;4:455–468.

# Classification of Surface Modifications

## Surface Passivation

phosphorylcholine

albumin

## Biomimetic Surface Functionalization

heparin

nitric oxide

direct thrombin inhibitor

## Endothelialization

*in vitro* preseeding

*in situ* capture

# VV extracorporeal life support for the Third Millennium: will we need anticoagulation?

Danny Eytan<sup>1</sup>, Yuval Bitterman<sup>1</sup>, Gail M. Annich<sup>2</sup>

<sup>1</sup>Department of Pediatric Critical Care, Rambam Medical Center, Haifa, Israel; <sup>2</sup>Department of Critical Care Medicine, The Hospital for Sick Children University of Toronto, Toronto, Canada

Correspondence to: Gail M. Annich, The Hospital for Sick Children University of Toronto, Toronto, Canada. Email: gail.annich@sickkids.ca.

Submitted Aug 25, 2017. Accepted for publication Nov 10, 2017.

Journal of Thoracic Disease, 2017

5

**Table 2** Characteristics of ideal extracorporeal surface modification

Characteristics	Heparin bonded	PPC	No releasing	No generating	Combination NO and DTI	EDC
Cover entire circuit	✓	?	✗	✓	±	✓
Longevity	✓	✓	✓	✓	✓	?
No systemic anticoagulation	✗	✗	✓	✓	✓	✓
Normal manufacture	✓	✓	✗	✗	✗	✗
Prevent thrombosis	✗	✗	✓	✓	✓	✓
Preserve platelet function	✗	✗	✓	✓	✓	✓
Reduce inflammation	±	±	✓	✓	✓	✓

PPC, phosphorylcholine; EDC, endothelialization; DTI, direct thrombin inhibitor; NO, nitric oxide.

# Thank You



UNIVERSITY OF TORONTO  
FACULTY OF MEDICINE

Healthier Children. A Better World.

**SickKids**  
THE HOSPITAL FOR  
SICK CHILDREN